Document Detail

Alteplase and tenecteplase: applications in the peripheral circulation.
MedLine Citation:
PMID:  11981795     Owner:  NLM     Status:  MEDLINE    
Alteplase (t-PA), a recombinant analogue of human tissue plasminogen activator, became the first genetically engineered thrombolytic approved by the Food and Drug Administration in 1987 for acute myocardial infarction (AMI). In addition to AMI, alteplase is currently approved for the treatment of acute ischemic stroke and pulmonary embolism, and we anticipate approval for catheter clearance in late 2001 in a 2-mg vial configuration. With the withdrawal of human neonatal kidney cell-derived urokinase, alteplase has become an alternative agent in peripheral vascular applications. Because few interventionalists had prior experience with the handling and dosage of alteplase, the Advisory Panel to the Society of Cardiovascular and Interventional Radiology established practice guidelines for use in noncoronary applications. Emerging clinical experience with contemporary dosing regimens shows a safety and efficacy profile similar to urokinase but with significantly reduced drug costs. Tenecteplase (TNK) is a genetically modified version of alteplase. TNK is the only plasminogen activator available that has shown a significantly enhanced safety profile versus alteplase in AMI. Approved for a 5-second, single-bolus injection in AMI, TNK possesses a longer half-life, increased resistance to plasminogen activator inhibitor, and improved fibrin specificity compared with alteplase. Because of its enhanced safety profile, TNK may be a desirable agent for peripheral vascular applications. Initial clinical studies with TNK in acute arterial and venous disease are ongoing. This article outlines the Advisory Panel guidelines for using alteplase and highlights features of tenecteplase.
C P Semba; K Sugimoto; M K Razavi;
Related Documents :
1571415 - Peripheral gangrene associated with kawasaki disease.
2936675 - Ergotamine-induced peripheral ischaemia reversed by oral thymoxamine hydrochloride.
8370015 - Thrombolytic therapy in peripheral arterial occlusive disease: mechanisms of action and...
3961285 - Febarbamate-induced pulmonary eosinophilia: a case report.
9237435 - Optimized transcranial doppler technique for the diagnosis of cardiac right-to-left shu...
18358965 - Pericarditis as initial manifestation of proximal aortic dissection in young patients.
Publication Detail:
Type:  Guideline; Journal Article; Practice Guideline; Review    
Journal Detail:
Title:  Techniques in vascular and interventional radiology     Volume:  4     ISSN:  1089-2516     ISO Abbreviation:  Tech Vasc Interv Radiol     Publication Date:  2001 Jun 
Date Detail:
Created Date:  2002-04-30     Completed Date:  2002-06-07     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9806675     Medline TA:  Tech Vasc Interv Radiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  99-106     Citation Subset:  IM    
Copyright Information:
Copyright 2001 by W.B. Saunders Company
Cardiovascular Clinical Research, Genentech Inc., MS 59, 1 DNA Way, South San Francisco, CA 94080-4990, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Circulation / drug effects
Dose-Response Relationship, Drug
Fibrinolytic Agents / pharmacology*,  standards,  therapeutic use*
Thrombolytic Therapy / standards
Tissue Plasminogen Activator / pharmacology*,  standards,  therapeutic use*
Treatment Outcome
United States
United States Food and Drug Administration
Urokinase-Type Plasminogen Activator / pharmacology,  standards,  therapeutic use
Vascular Patency / drug effects
Reg. No./Substance:
0/Fibrinolytic Agents; 0/tenecteplase; EC Plasminogen Activator; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bleeding complications associated with the use of rt-PA versus r-PA for peripheral arterial and veno...
Next Document:  The use of glycoprotein IIb/IIIa antagonists in peripheral arterial occlusion.